FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ryuya Yamanaka

Research Profile

Disorders

Anatomy

Living Beings

Procedures

Physiology

Chemicals & Drugs

Co-author Network

Publications

TOP 3
Atsushi Kawaguchi; Tsutomu Kobayashi; Yoshihiro Komohara; Yuko Sakai; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Hiroshi Aoki; Yukihiko Fujii; Junpei Homma; Hiroaki Hondoh; Yasuo Iwadate; Koji Kajiwara; Tatsuyuki Kakuma; Ryuya Yamanaka
Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma.
Ryuya Yamanaka; Ken Morii; Yoshikatsu Shinbo; Junpei Homma; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Tetsuro Tamura; Hiroaki Hondoh; Hitoshi Takahashi; Tatsuyuki Kakuma; Ryuichi Tanaka
Results of treatment of 112 cases of primary CNS lymphoma.
Ryuya Yamanaka; Junpei Homma; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Hideaki Takahashi; Yoshikatsu Shinbo; Akira Hasegawa; Takashi Saitoh; Ryuichi Tanaka
Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ryuya Yamanaka (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Atsushi Kawaguchi; Tsutomu Kobayashi; Yoshihiro Komohara; Yuko Sakai; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Hiroshi Aoki; Yukihiko Fujii; Junpei Homma; Hiroaki Hondoh; Yasuo Iwadate; Koji Kajiwara; Tatsuyuki Kakuma; Ryuya Yamanaka
Gene expression signature-based prognostic risk score in patients with primary central nervous system lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(20):5672-81.
2008: Ryuya Yamanaka; Ken Morii; Yoshikatsu Shinbo; Junpei Homma; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Tetsuro Tamura; Hiroaki Hondoh; Hitoshi Takahashi; Tatsuyuki Kakuma; Ryuichi Tanaka
Results of treatment of 112 cases of primary CNS lymphoma.
Japanese journal of clinical oncology 2008;38(5):373-80.
2007: Ryuya Yamanaka; Junpei Homma; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Hideaki Takahashi; Yoshikatsu Shinbo; Akira Hasegawa; Takashi Saitoh; Ryuichi Tanaka
Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
Leukemia & lymphoma 2007;48(7):1429-33.
2007: Ryuya Yamanaka; Yoshikatsu Shinbo; Masakazu Sano; Junpei Homma; Naoto Tsuchiya; Naoki Yajima; Tetsuro Tamura; Hiroaki Hondoh; Hideaki Takahashi; Ken Morii; Kiyoshi Onda; Ryuichi Tanaka
Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Leukemia & lymphoma 2007;48(6):1119-26.
2007: Ryuya Yamanaka; Junpei Homma; Masakazu Sano; Naoto Tsuchiya; Naoki Yajima; Yoshikatsu Shinbo; Akira Hasegawa; Kiyoshi Onda; Ryuichi Tanaka
Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Leukemia & lymphoma 2007;48(5):1019-22.
2006: Masakazu Sano; Nobuyuki Genkai; Naoki Yajima; Naoto Tsuchiya; Junpei Homma; Ryuichi Tanaka; Toru Miki; Ryuya Yamanaka
Expression level of ECT2 proto-oncogene correlates with prognosis in glioma patients.
Oncology reports 2006;16(5):1093-8.
2006: Ryuya Yamanaka; T Arao; Naoki Yajima; Naoto Tsuchiya; Junpei Homma; Ryuichi Tanaka; Masakazu Sano; A Oide; Masaru Sekijima; Kazuto Nishio
Identification of expressed genes characterizing long-term survival in malignant glioma patients.
Oncogene 2006;25(44):5994-6002.
2006: Nobuyuki Genkai; Junpei Homma; Masakazu Sano; Ryuichi Tanaka; Ryuya Yamanaka
Increased expression of pituitary tumor-transforming gene (PTTG)-1 is correlated with poor prognosis in glioma patients.
Oncology reports 2006;15(6):1569-74.
2006: Junpei Homma; Ryuya Yamanaka; Naoki Yajima; Naoto Tsuchiya; Nobuyuki Genkai; Masakazu Sano; Ryuichi Tanaka
Increased expression of CCAAT/enhancer binding protein beta correlates with prognosis in glioma patients.
Oncology reports 2006;15(3):595-601.
2005: Naoto Tsuchiya; Ryuya Yamanaka; Naoki Yajima; Junpei Homma; Masakazu Sano; Tadashi Komata; Takeshi Ikeda; Ichiro Fujimoto; Hitoshi Takahashi; Ryuichi Tanaka; Kazuhiro Ikenaka
Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines.
International journal of oncology 2005;27(5):1231-9.
2005: Naoki Yajima; Ryuya Yamanaka; Ryuichi Tanaka; Minoru Shigemori; Takashi Mine; Kyougo Itoh
[CTL precursor-oriented peptide vaccine therapy for malignant glioma].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 9():582-7.
2005: Ryuya Yamanaka; Ken Morii; Hideaki Takahashi; Ryuichi Tanaka; Kazuto Nishio
[Analysis of gene expression profiles in malignant brain tumors with respect to sensitivity to therapies].
Nihon rinsho. Japanese journal of clinical medicine 2005;63 Suppl 9():49-54.
2005: Naoki Yajima; Ryuya Yamanaka; Takashi Mine; Naoto Tsuchiya; Junpei Homma; Masakazu Sano; Terukazu Kuramoto; Yayoi Obata; Nobukazu Komatsu; Yoshimi Arima; Akira Yamada; Minoru Shigemori; Kyogo Itoh; Ryuichi Tanaka
Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5900-11.
2005: Ryuya Yamanaka; Ken Morii; Yoshikatsu Shinbo; Shigekazu Takeuchi; Tetsuro Tamura; Hiroaki Hondoh; Hitoshi Takahashi; Kiyoshi Onda; Hideaki Takahashi; Ryuichi Tanaka
Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Annals of hematology 2005;84(7):447-55.
2005: Ryuya Yamanaka; Junpei Homma; Naoki Yajima; Naoto Tsuchiya; Masakazu Sano; Tsutomu Kobayashi; Seiichi Yoshida; Takashi Abe; Miwako Narita; Masuhiro Takahashi; Ryuichi Tanaka
Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(11):4160-7.
2005: Ryuya Yamanaka; Kleanthis G Xanthopoulos
Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
DNA and cell biology 2005;24(5):317-24.
2005: Ryuya Yamanaka; Junpei Honma; Naoto Tsuchiya; Naoki Yajima; Tsutomu Kobayashi; Ryuichi Tanaka
Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma.
Journal of neuro-oncology 2005;72(2):107-13.
2004: Ryuya Yamanaka; Ryuichi Tanaka
Gene therapy of brain tumor with endostatin.
Drugs of today (Barcelona, Spain : 1998) 2004;40(11):931-4.
2004: Ryuya Yamanaka; Ryuichi Tanaka
Advances for the treatment of primary central nervous system lymphoma (review).
Oncology reports 2004;12(3):563-8.
2004: Ryuya Yamanaka
Alphavirus vectors for cancer gene therapy (review).
International journal of oncology 2004;24(4):919-23.
2004: Ryuya Yamanaka; Kleanthis G Xanthopoulos
Development of improved Sindbis virus-based DNA expression vector.
DNA and cell biology 2004;23(2):75-80.
2003: Gen Sato; Ryuichi Tanaka; Katsuhiko Akiyama; Ryuya Yamanaka; Mitsuya Sato
Immunohistochemical analysis of myelination following hemicranial irradiation in neonatal rats.
Neuroscience letters 2003;353(2):131-4.
2003: Ryuya Yamanaka; Takashi Abe; Naoki Yajima; Naoto Tsuchiya; Junpei Homma; Tsutomu Kobayashi; Miwako Narita; Masuhiro Takahashi; Ryuichi Tanaka
Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
British journal of cancer 2003;89(7):1172-9.
2003: Ryuya Yamanaka; Naoto Tsuchiya; Naoki Yajima; Junpei Honma; Hitoshi Hasegawa; Ryuichi Tanaka; Jay Ramsey; R. Michael Blaese; Kleanthis G Xanthopoulos
Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12.
Journal of neurosurgery 2003;99(4):746-53.
2003: Ryuya Yamanaka; Shigeru Akutagawa; Fumiko Taguchi; Naoki Yajima; Naoto Tsuchiya; Takeo Uzuka; Ken Morii; Hideaki Takahashi; Ryuichi Tanaka; Nagahiro Saijo; Kazuto Nishio
Selection of surrogate marker genes in primary central nervous system lymphomas for radio-chemotherapy by DNA array analysis of gene expression profiles.
International journal of oncology 2003;23(4):913-23.
2003: Tsutomu Kobayashi; Ryuya Yamanaka; Junpei Homma; Naoto Tsuchiya; Naoki Yajima; Seiichi Yoshida; Ryuichi Tanaka
Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma.
Cancer immunology, immunotherapy : CII 2003;52(10):632-7.
2003: Ryuya Yamanaka; Junpei Homma; Naoki Yajima; Naoto Tsuchiya; Ryuichi Tanaka
[Dendritic cell therapy for malignant glioma].
Nō to shinkei = Brain and nerve 2003;55(9):771-80.
2003: Ryuya Yamanaka; Naoki Yajima; Takashi Abe; Naoto Tsuchiya; Junpei Homma; Miwako Narita; Masuhiro Takahashi; Ryuichi Tanaka
Dendritic cell-based glioma immunotherapy (review).
International journal of oncology 2003;23(1):5-15.
2003: Youji Soga; Ryuya Yamanaka; Kazuhiko Nishino; Ryuichi Tanaka
CCAAT/enhancer binding proteins are expressed in the gerbil hippocampus after transient forebrain ischemia.
Neuroscience letters 2003;337(2):106-10.
2002: Ryuya Yamanaka; Naoki Yajima; Naoto Tsuchiya; Junpei Honma; Ryuichi Tanaka; Jay Ramsey; Michael Blaese; Kleanthis G Xanthopoulos
Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA.
Journal of neurosurgery 2002;97(5):1184-90.
2002: Ryuya Yamanaka; Susan A Zullo; Jay Ramsey; Naoki Yajima; Naoto Tsuchiya; Ryuichi Tanaka; Michael Blaese; Kleanthis G Xanthopoulos
Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12.
Journal of neurosurgery 2002;97(3):611-8.
2001: Ryuya Yamanaka; Susan A Zullo; Jay Ramsey; M Onodera; Ryuichi Tanaka; Michael Blaese; Kleanthis G Xanthopoulos
Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus.
Cancer gene therapy 2001;8(10):796-802.
2001: Ryuya Yamanaka; Susan A Zullo; Ryuichi Tanaka; Michael Blaese; Kleanthis G Xanthopoulos
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA.
Journal of neurosurgery 2001;94(3):474-81.
2000: Ryuya Yamanaka; Susan A Zullo; Ryuichi Tanaka; Jay Ramsey; Michael Blaese; Kleanthis G Xanthopoulos
Induction of a therapeutic antitumor immunological response by intratumoral injection of genetically engineered Semliki Forest virus to produce interleukin-12.
Neurosurgical focus 2000;9(6):e7.
1999: Ryuya Yamanaka; Ryuichi Tanaka; S Yoshida; T Saitoh; K Fujita; H Naganuma
Suppression of TGF-beta1 in human gliomas by retroviral gene transfection enhances susceptibility to LAK cells.
Journal of neuro-oncology 1999;43(1):27-34.
1998: Ryuya Yamanaka; Julie Lekstrom-Himes; Carrolee Barlow; Anthony Wynshaw-Boris; Kleanthis G Xanthopoulos
CCAAT/enhancer binding proteins are critical components of the transcriptional regulation of hematopoiesis (Review).
International journal of molecular medicine 1998;1(1):213-21.
1997: Ryuya Yamanaka; Carrolee Barlow; Julie Lekstrom-Himes; Lucio H Castilla; P Paul Liu; Michael Eckhaus; T Decker; Anthony Wynshaw-Boris; Kleanthis G Xanthopoulos
Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(24):13187-92.
1997: Ryuya Yamanaka; G D Kim; H S Radomska; Julie Lekstrom-Himes; L T Smith; P Antonson; Daniel G Tenen; Kleanthis G Xanthopoulos
CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(12):6462-7.
1996: P Antonson; B Stellan; Ryuya Yamanaka; Kleanthis G Xanthopoulos
A novel human CCAAT/enhancer binding protein gene, C/EBPepsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus.
Genomics 1996;35(1):30-8.